514 related articles for article (PubMed ID: 19224107)
1. Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects.
Roser P; Gallinat J; Weinberg G; Juckel G; Gorynia I; Stadelmann AM
Eur Arch Psychiatry Clin Neurosci; 2009 Aug; 259(5):284-92. PubMed ID: 19224107
[TBL] [Abstract][Full Text] [Related]
2. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC.
Ménétrey A; Augsburger M; Favrat B; Pin MA; Rothuizen LE; Appenzeller M; Buclin T; Mangin P; Giroud C
J Anal Toxicol; 2005; 29(5):327-38. PubMed ID: 16105257
[TBL] [Abstract][Full Text] [Related]
3. The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Δ
Boggs DL; Cortes-Briones JA; Surti T; Luddy C; Ranganathan M; Cahill JD; Sewell AR; D'Souza DC; Skosnik PD
J Psychopharmacol; 2018 Dec; 32(12):1308-1318. PubMed ID: 30255720
[TBL] [Abstract][Full Text] [Related]
4. Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity.
Juckel G; Roser P; Nadulski T; Stadelmann AM; Gallinat J
Schizophr Res; 2007 Dec; 97(1-3):109-17. PubMed ID: 17884351
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
[TBL] [Abstract][Full Text] [Related]
6. Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.
Roser P; Juckel G; Rentzsch J; Nadulski T; Gallinat J; Stadelmann AM
Eur Neuropsychopharmacol; 2008 Aug; 18(8):569-77. PubMed ID: 18544469
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
[TBL] [Abstract][Full Text] [Related]
8. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.
El-Alfy AT; Ivey K; Robinson K; Ahmed S; Radwan M; Slade D; Khan I; ElSohly M; Ross S
Pharmacol Biochem Behav; 2010 Jun; 95(4):434-42. PubMed ID: 20332000
[TBL] [Abstract][Full Text] [Related]
9. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
10. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users.
Spindle TR; Cone EJ; Goffi E; Weerts EM; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
Drug Alcohol Depend; 2020 Jun; 211():107937. PubMed ID: 32247649
[TBL] [Abstract][Full Text] [Related]
12. Sex differences in the subjective effects of oral Δ
Fogel JS; Kelly TH; Westgate PM; Lile JA
Pharmacol Biochem Behav; 2017 Jan; 152():44-51. PubMed ID: 26780348
[TBL] [Abstract][Full Text] [Related]
13. Sex differences in the acute effects of oral and vaporized cannabis among healthy adults.
Sholler DJ; Strickland JC; Spindle TR; Weerts EM; Vandrey R
Addict Biol; 2021 Jul; 26(4):e12968. PubMed ID: 32985064
[TBL] [Abstract][Full Text] [Related]
14. Acute psychotropic effects of oral cannabis extract with a defined content of Delta9-tetrahydrocannabinol (THC) in healthy volunteers.
Kaufmann RM; Kraft B; Frey R; Winkler D; Weiszenbichler S; Bäcker C; Kasper S; Kress HG
Pharmacopsychiatry; 2010 Jan; 43(1):24-32. PubMed ID: 20178093
[TBL] [Abstract][Full Text] [Related]
15. Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC.
Hunault CC; Mensinga TT; de Vries I; Kelholt-Dijkman HH; Hoek J; Kruidenier M; Leenders ME; Meulenbelt J
Psychopharmacology (Berl); 2008 Dec; 201(2):171-81. PubMed ID: 18695931
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans.
Wachtel SR; ElSohly MA; Ross SA; Ambre J; de Wit H
Psychopharmacology (Berl); 2002 Jun; 161(4):331-9. PubMed ID: 12073159
[TBL] [Abstract][Full Text] [Related]
17. Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.
Karschner EL; Swortwood MJ; Hirvonen J; Goodwin RS; Bosker WM; Ramaekers JG; Huestis MA
Drug Test Anal; 2016 Jul; 8(7):682-9. PubMed ID: 26097154
[TBL] [Abstract][Full Text] [Related]
18. A randomised, placebo-controlled, double blind, crossover trial on the effect of a 20:1 cannabidiol: Δ9-tetrahydrocannabinol medical cannabis product on neurocognition, attention, and mood.
Manning B; Hayley AC; Catchlove S; Stough C; Downey LA
Eur Neuropsychopharmacol; 2024 May; 82():35-43. PubMed ID: 38490083
[TBL] [Abstract][Full Text] [Related]
19. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids.
Goodwin RS; Gustafson RA; Barnes A; Nebro W; Moolchan ET; Huestis MA
Ther Drug Monit; 2006 Aug; 28(4):545-51. PubMed ID: 16885723
[TBL] [Abstract][Full Text] [Related]
20. Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THC.
Lile JA; Kelly TH; Hays LR
Drug Alcohol Depend; 2011 Jul; 116(1-3):86-92. PubMed ID: 21227600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
